Abstract: This invention refers to a pharmaceutical composition that comprises the synergic combination of a NSAID, such as the active ingredient: S-ketorolac of tromethamine and a GABA derivative agent, such as the active ingredient: gabapentin, which are formulated with pharmaceutically acceptable excipients in a single dosing unit to be administered by oral, parenteral, topical, transdermal means or with the use of transdermal, oral or nasal inhalation devices, which is indicated for the treatment of neuropathic and/or nociceptive pain caused by different etiologies.

Abstract: The present invention refers to the synergic combination of a non-steroid anti-inflammatory agent such as ketorolac or its S-ketorolac isomer or pharmaceutically acceptable salts thereof and a gamma-aminobutyric (GABA) neurotransmitter analog agent from the group of neuromodulators, such as the active principle pregabalin or pharmaceutically acceptable salts thereof, wherein said combination is useful to be formulated as a pharmaceutical combination to be administered by oral route, indicated for the treatment of neuropathic pain in patients with recurrent neuropathic pain or for post-surgical patients, and as an analgesic and anti-inflammatory therapy.

Abstract: The present invention refers to a pharmaceutical combination comprising the synergic combination of a selective cyclooxygenase-2 inhibitor, such as the active principle celecoxib and pharmaceutically acceptable salts thereof, and a guaifenesin-derived carbamate such as the active principle methocarbamol and pharmaceutically acceptable salts thereof, formulated with pharmaceutically acceptable excipients and/or carriers and/or additives, in a single dosing unit to be administered orally, dermally or transdermally or topically, indicated for the treatment of pain, inflammation and muscular contractions; said combination triggers a triple effect: analgesic, anti-inflammatory and muscle relaxant, being better tolerated and with less adverse effects in patients with pain, inflammation and muscular contractions.

Abstract: The present invention is related to a pharmaceutical composition comprising the synergic pharmaceutical combination of a non-steroidal anti-inflammatory drug such as aceclofenac or pharmaceutically acceptable salts thereof and a steroidal anti-inflammatory drug such as the active principle betamethasone or pharmaceutically acceptable phosphate or dipropionate salts thereof, formulated for administration by intramuscular or intravenous route, for the treatment and control of local rheumatic pain and for post-surgery patients.

Abstract: The present invention refers to a pharmaceutical combination comprising the synergic combination of a leukotriene-receptor antagonist such as the active principle montelukast and pharmaceutically acceptable salts thereof, and an histamine H1 inverse agonist such as the active principle ketotifen and pharmaceutically acceptable salts thereof, formulated with pharmaceutically acceptable excipients and/or carriers and/or additives, in a single dosing unit to be administered orally, transdermally or in devices for oral or nasal inhalation, indicated for the treatment of an atopic disease such as asthma, allergic rhinitis and atopic dermatitis.

Abstract: This invention refers to a pharmaceutical composition that comprises the synergic combination of a selective COX-2 inhibitor, such as the active ingredient: celecoxib and an anthraquinone derivative agent, such as the active ingredient: diacerein, which are formulated with pharmaceutically acceptable excipients and/or vehicles and/or additives in a single dosing unit to be administered by oral, parenteral, topical, transdermal means or with the use of transdermal, oral or nasal inhalation devices, which is indicated for the treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and/or degenerative joint disease caused by different etiologies.

Abstract: This invention is related to a pharmaceutical composition made up by the synergic combination of a nonsteroidal anti-inflammatory analgesic such as Aceclofenac or its pharmaceutically acceptable salts and an anti-inflammatory steroid agent such as the active ingredient Betamethasone or its pharmaceutically acceptable phosphate or dipropionate salts, which are formulated in a single dosing unit for topical, intramuscular or intravenous administration, which is indicated for the treatment of the localized pain of rheumatic diseases.

Abstract: This invention refers to a pharmaceutical composition that comprises the synergic combination of a NSAID, such as the active ingredient: S-ketorolac of tromethamine and a GABA derivative agent, such as the active ingredient: gabapentin, which are formulated with pharmaceutically acceptable excipients in a single dosing unit to be administered by oral, parenteral, topical, transdermal means or with the use of transdermal, oral or nasal inhalation devices, which is indicated for the treatment of neuropathic and/or nociceptive pain caused by different etiologies.

Abstract: The invention relates to a novel chemical compound characterized in that it contains the active enantiomer S-(?) ketorolac tromethamine combined with other pharmaceutically acceptable adjuvants or excipients, said compound being advantageous over other NSAIDs and, in particular, the known active principle ketorolac tromethamine, comprising a single isomer that is pure and has a better therapeutic index, retaining its therapeutic activity by improving its physicochemical properties, such as solubility or stability, which translates into a decrease in the dose administered, reducing direct gastrointestinal side effects and the time required for the development of the desired therapeutic action. The invention is suitable for use as a medication for the treatment of pain of moderate to high intensity and can be administered in any form in the dose range from 0.5 milligrams to 30 milligrams.

Abstract: The present invention relates to a pharmaceutical composition comprising the synergistic combination of a non-steroidal anti-inflammatory drug (NSAID), such as the active ingredient s-ketorolac tromethamine, and an opioid agent, such as the active ingredient tramadol chlorhydrate, which ingredients are formulated with pharmaceutically acceptable excipients. The composition is used for the control and treatment of mild and/or moderate and/or severe pain.